Patent · US Active

Method for treating cancer

US9889138B2 · kind B2 · utility

9Cited by
4References
35Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJul 15, 2016
Grant dateFeb 13, 2018
Priority date
Expiry dateJul 15, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K31/5375
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.